RxDoctor Payments Data

Anthony Bleyer, MD

Nephrology · Winston Salem, NCNPI 1346225778

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $17,420 of the $19,874 with a category attached, or 87.7%. Amgen accounts for 98.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $8,725 and has fallen 99.2% since, to $72 in 2025. Among nephrology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,874in general payments, 2019–2025

Across 21 payments — averaging $946.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$20K
  • Novartis$80
  • Bard Peripheral Vascular, Inc.$73
  • Alnylam Pharmaceuticals Inc.$72
$65,479in research payments, 2019–2025

Across 26 payments — averaging $2518.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$37K
  • Ardelyx, Inc.$28K

What the payments were for

  • Consulting fees$910%
  • Speaking & faculty fees$17,42088%
  • Travel & lodging$1,7019%
  • Food & beverage$6623%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)18$19,649
Novartis1$80
Bard Peripheral Vascular, Inc.1$73
Alnylam Pharmaceuticals Inc.1$72

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,874 in reported general payments places this provider in the 90th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$64,203
Medicare patients
126
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$83,699
FarxigaDapagliflozin Propanediol24$28,444
Sevelamer Carbonate74$16,440
ClinolipidFat Emulsion/Olive/Soy/Phospho45$9,355
ProsolParenteral Amino Acid 20% No.144$6,615
Potassium Citrate ErPotassium Citrate22$2,384
Metolazone44$2,034
Eplerenone17$1,894
Bumetanide18$1,171
Labetalol Hcl45$1,000
Losartan Potassium85$762
Amlodipine Besylate91$720
Potassium Chloride27$709
Calcium Acetate17$594
Allopurinol47$593

Paid to pharmacies, not to this prescriber.

Other nephrology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →